CTLA4 and cutaneous melanoma: Hence, it is not completely surprising that responses to ICI have been disappointing, especially in contrast to cutaneous melanoma, with ORR < 5% to agents blocking the PD-(L)1 axis alone [12], 0–8% to anti-Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) alone [13–15], and 11.5–18% to anti-PD-1 + CTLA-4 [16–18].